## 50/0

## CLAIMS

1. (Amended) A quinazoline derivative having the following formula (1) and a pharmaceutically acceptable salt thereof:

$$X \xrightarrow{H} O \xrightarrow{R^1} R^1$$

$$O \xrightarrow{O_2} R^3$$

$$R^2$$

wherein the ring A represents an aryl group;

R1 represents a hydroxyl group, an amino group, a C1 to C4 lower\alkylamino group which may be substituted with a carb $\alpha$ xylic acid group, a  $C_7$  to  $C_{10}$  lower aralkylamino group which \may be substituted with a carboxylic acid group, an amino group acylated with a  $C_1$  to  $C_4$  lower aliphatic acid which may be substituted with a carboxylic acid group, an amino group acylated with an aromatic ring carboxylic acid which may be \substituted with a carboxylic acid group, an amino group achlated with a heteroaromatic ring carboxylic acid which may be substituted with a . carboxylic acid group, an amino  $\group$  sulfonylated with a  $C_1$ to  $C_4$  lower alkanesulfonic acid which may be substituted with a carboxylic acid group, an amino\group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid group, a  $C_1$  to  $\backslash C_4$  lower alkyl group substituted with a carboxylic acid group, or a  $C_2$  to  $C_4$  lower alkylene group which may be substituted with a carboxylic acid group;

 $R^2$  and  $R^3$  may be the same or different and represent a hydrogen atom, an unsubstituted or substituted  $C_1$  to  $C_4$  lower alkyl group, a halogen atom, a hydroxyl group, a  $C_1$  to  $C_4$  lower alkoxyl group, an amino group, an unsubstituted or substituted  $C_1$  to  $C_4$  lower

OSZEIZ OHIZO

Departed makes

doreacta outeo:

alkylamino group, an unsubstituted or substituted  $C_7$  to  $C_{10}$  aralkylamino group, an amino group acylated with a  $C_1$  to  $C_4$  lower aliphatic acid which may be substituted with a carboxylic acid group, an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a  $C_1$  to  $C_4$  lower alkanesulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid group, or a carboxylic acid group, or a

when the ring A is a benzene ring,  $R^1$  and  $R^2$  may form, together with the substituting benzene ring, a fused heterocyclic ring which may be substituted with a carboxylic acid and in which the carbon atom in the ring may form a carbonyl group and  $R^3$  is the same as defined above; and

X represents a hydrogen atom, a  $C_1$  to  $C_4$  lower alkyl group, a  $C_1$  to  $C_4$  lower alkoxy group, a halogen atom, a hydroxyl group, an amino group, or a nitro group, with the proviso that, when the ring A is a benzene ring,  $R^1$  is an amino group and both  $R^2$  and  $R^3$  are a hydrogen atom,  $R^1$  is not positioned at the para-position to the sulfonyl group.

- 2. A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, in the formula (1),  $R^1$  is a hydroxyl group, an amino group, a  $C_1$  to  $C_4$  lower alkylamino group substituted with a carboxylic acid group, or an amino group acylated with a  $C_1$  to  $C_4$  lower aliphatic acid substituted with a carboxylic acid group.
- 3. A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1 or 2, wherein,

Subj Bl in the formula (1),  $R^2$  is a carboxylic acid group or a hydrogen atom.

4. A quinaxoline derivative or a pharmaceutically

D9763213 .O41201

5 M

acceptable salt thereof as claimed in any one of claims 1 to 3, wherein R<sup>3</sup> in the formula (I) is a hydrogen atom.

- 5. A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier therefor.
- 6. A chymase inhibitor having as an effective ingredient a quinazoline derivative or its pharmaceutically salt according to any one of claims 1 to 4.

for prevention or treatment of allergic diseases or rheumatic diseases.

- 8. A pharmaceutical composition as claimed in claim 5 for prevention or treatment of bronchial asthma, eczema, atopic dermatitis, mastocytosis, scleriasis, or rheumatoid arthritis.
- 9. A pharmaceutical composition as claimed in claim 5 for prevention or treatment of cardiac and circulatory system diseases due to the abnormal exacerbation of Angiotensin II production.
- 10. A pharmaceutical composition as claimed in claim 5 for prevention or treatment of cardiac insufficiency, hypercardia, stasis cardiac diseases, hypertension, arteriosclerosis, peripheral circulatory diseases, revasoconstriction after PTCA, diabetic renal disorders or non-diabetic renal disorders, coronary diseases including cardiac infarction, angioendothelia, or vascular disorders accompanying arterialization and atheroma.
- 11. (Amended) A sulfonylurea derivative having the formula (4):

COPPEZETT CHIECI

$$X \stackrel{H}{\longrightarrow} CO_2H \stackrel{H}{\longrightarrow} CO_2 \stackrel{R^3}{\longrightarrow} R^2 \stackrel{R^3}{\longrightarrow} (4)$$

wherein the ring A represents an aryl group;

5

10

20

25

30

35

R1, is R1, which may be protected with a protecting group, and which represents a hydroxyl group, an amino group, a C<sub>1</sub> to C<sub>4</sub> lower alkylamino group which may be substituted with a carboxylic acid group, a C, to C<sub>10</sub> lower aralkylamino group which may be substituted with a carboxylic acid group, an amino group acylated with a C1 to C4 lower aliphatic acid which may be substituted with a carboxylic acid group, an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with\a C<sub>1</sub> to C<sub>4</sub> lower alkanesulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid group, a C, to C, lower alkyl group substituted with a carboxylic acid group, or a C2 to C4 lower alkylene group which may be substituted with a carboxylic acid group;


 $R^2$ ' and  $R^3$ ' are  $R^2$  and  $R^3$ , respectively, which may be protected with a protecting group, which may be the same or different, and which represent a hydrogen atom, an unsubstituted or substituted  $C_1$  to  $C_4$  lower alkyl group, a halogen atom, a hydroxyl group, a  $C_1$  to  $C_4$  lower alkoxyl group, an amino group, an unsubstituted or substituted  $C_1$  to  $C_4$  lower alkylamino group, an unsubstituted or substituted  $C_7$  to  $C_{10}$  aralkylamino group,

an amino group acylated with a  $C_1$  to  $C_4$  lower aliphatic acid which may be substituted with a carboxylic acid group, an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a  $C_1$  to  $C_4$  lower alkanesulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid group, or a carboxylic acid group or

when the ring A is a benzene ring,  $R^1$  and  $R^2$  may form, together with the substituting benzene ring, a fused heterocyclic ring which may be substituted with a carboxylic acid and in which the carbon atom in the ring may form a carbonyl group and  $R^3$  is the same as defined above; and

X' is X, which may be protected with a protecting group and which represents a hydrogen atom, a  $C_1$  to  $C_4$  lower alkyl group, a  $C_1$  to  $C_4$  lower alkoxyl group, a halogen atom, a hydroxyl group, an amino group, or a nitro group, with the proviso that, when the ring A is a benzene ring,  $R^1$  is an amino group and both  $R^2$  and  $R^3$  are a hydrogen atom,  $R^1$  is not positioned at the para-position to the sulfonyl group.

12. (Amended) A sulfonylurea derivative having the formula (7):



wherein, the ring A represents an aryl group;

 $R^{1}$  is  $R^{1}$ , which may be protected with a protecting group and which represents a hydroxyl group,

OG763213 OH1201

an amino group, a C1 to C4 lower alkylamino group which may be substituted with a carboxylic acid group, a C, to C10 lower aralkylamino group which may be substituted with a carboxylic acid group, an amino group acylated with a C, to C, lower aliphatic acid which may be substituted with a carboxylic acid group, an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a C, to C, lower alkanesulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid group, a C, to C4 lower alkyl group substituted with a carboxylic acid group, or a C, to C, lower alkylene group which may be substituted with a carboxylic acid group;

5

10

15

20

25

30

35

 $R^2$ ' and  $R^3$ ' are  $R^2$  and  $R^3$ , respectively, which may be protected with a protecting group, which may be the same or different and which represent a hydrogen atom, an unsubstituted or substituted C, to C, lower alkyl group, a halogen atom, a hydroxyl group, a C1 to C4 lower alkoxyl group, an amino group, an unsubstituted or substituted C, to C, lower alkylamino group, an unsubstituted or substituted C<sub>7</sub> to C<sub>10</sub> lower aralkylamino group, an amino group acylated with a C<sub>1</sub> to C<sub>4</sub> lower aliphatic acid which may be substituted with a carboxylic acid group, an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group acylated\with a heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a C1 to C4 lower alkanesulfonic acid which may be substituted with a carboxylic acid group, an ART 34 AMDT

amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid group, or a carboxylic acid group or

when the ring A is a benzene ring,  $R^1$  and  $R^2$  may form together with the substituting benzene ring a fused heterocyclic ring which may be substituted with a carboxylic acid and in which the carbon atom in the ring may form a carbonyl group and  $R^3$  is the same as defined above;

R4 represents a protecting group for a

carboxyl group; and

X' is X, which may be protected with a protecting group and which represents a hydrogen atom, a  $C_1$  to  $C_4$  lower alkyl group, a  $C_4$  to  $C_4$  lower alkoxy group, a halogen atom, a hydroxyl group, an amino group, or a nitro group, with the proviso that, when the ring A is a benzene ring,  $R^1$  is an amino group and both  $R^2$  and  $R^3$  are a hydrogen atom,  $R^1$  is not positioned at the para-position to the sulfonyl group.

13. A method for producing a quinazoline derivative having the formula (1) according to claim 1 comprising:

allowing a sulfonylurea derivative having the formula (4) according to claim 11 to a ring-closing reaction with a condensation agent or

deprotecting a carboxyl group of the sulfonylurea derivative having the formula (7) according to claim 12, followed by effecting a ring-closing reaction with a condensation agent.

add Ei